Asma Hashmi, MD
Psychiatry · Oklahoma City, OKNPI 1598027971
Payments from drug & device makers
Across 61 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$286
- Johnson & Johnson$173
- Vanda Pharmaceuticals Inc.$151
- Neuronetics, Inc.$113
- Teva Pharmaceuticals USA, Inc.$83
- Otsuka America Pharmaceutical, Inc.$63
- plus $271 from 11 others
What the payments were for
- Food & beverage$1,09796%
- Education$424%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $286 |
| Johnson & Johnson | 8 | $173 |
| Vanda Pharmaceuticals Inc. | 7 | $151 |
| Neuronetics, Inc. | 4 | $113 |
| Teva Pharmaceuticals USA, Inc. | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Alkermes, Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $33 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Avanir Pharmaceuticals, Inc. | 1 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Indivior Inc. | 1 | $14 |
How this compares
$1,139 in reported general payments places this provider in the 75th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 31 | $930 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $726 |
| Trazodone Hcl | 37 | $639 |
| Quetiapine Fumarate | 11 | $348 |
| Aripiprazole | 22 | $323 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $192 |
| Fluvoxamine Maleate | 12 | $143 |
| Clonazepam | 11 | $124 |
| Escitalopram Oxalate | 11 | $116 |
| Lorazepam | 24 | $101 |
| Eszopiclone | 11 | $59 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Oklahoma City
- Louise ThurmanOklahoma City$6.2M
- Veronique SebastianOklahoma City$3.8M
- Marvin PeytonOklahoma City$3.2M
- Willis HollowayOklahoma City$1.4M
- Courtney NixonOklahoma City$1.2M
- Surinder RandhawaOklahoma City$142K
- Adonis Al BotrosOklahoma City$73K
- Josephine DeguzmanOklahoma City$38K
- Haisam Al KhouriOklahoma City$10K
- Patrick HornOklahoma City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.